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Abstract Determining how antibiotics inhibit ribosomal activity 
requires a detailed understanding of the interactions and relative 
movement of tRNA, mRNA and the ribosome. Recent models for 
the formation of hybrid tRNA binding sites during the elongation 
cycle have provided a basis for re-evaluating earlier experimental 
data and, especially, those relevant to substrate movements 
through the peptidyl transferase centre. With the exception of 
deacylated tRNA, which binds at the E-site, ribosomal interac-
tions of the 3'-ends of the tRNA substrates generate only a small 
part of the total free energy of tRNA-ribosome binding. 
Nevertheless, these relatively weak interactions determine the 
unidirectional movement of tRNAs through the ribosome and, 
moreover, they appear to be particularly susceptible to 
perturbation by antibiotics. Here we summarise current ideas 
relating particularly to the movement of the 3'-ends of tRNA 
through the ribosome and consider possible inhibitory mecha-
nisms of the peptidyl transferase antibiotics. 
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1. Introduction 
The concept of hybrid sites for tRNA binding on the ribo-
some has radically changed our view of how peptide elonga-
tion occurs. The early hypothesis that such sites can form [1-
3] has received experimental support from footprinting of 
tRNA-ribosome complexes [4] and from kinetic studies on 
the puromycin reaction [5-7]. Their formation can also facil-
itate proof-reading of amino acid incorporation [8]. Hybrid 
tRNA sites form the basis of the 'hybrid state' model for 
elongation [4] that is illustrated, in modified form, in Fig. 1. 
This model provides a basis for reinterpreting the extensive 
early literature on the binding of various tRNA substrates to 
the ribosome and on the binding and mode of action of the 
peptidyl transferase drugs [9]. Here, we try to rationalise fur-
ther the molecular bases of inhibition by these drugs. Partic-
ular attention is paid to the thermodynamics and kinetics of 
the elongation process and we refer primarily to the bacterial 
(Escherichia coli) ribosome. 
2. tRNA binding sites 
The strongest tRNA-ribosome interactions take place on 
the small ribosomal subunit. They are codon-dependent and 
occur at the acceptor A- and peptidyl P-sites within the 
mRNA binding centre [10,11]. Deacylated tRNA binds pri-
marily to the exit (E) site on the large subunit [12-16]. The 
remaining tRNA-ribosome interactions, including those at the 
peptidyl transferase centre of the large subunit [17], are all 
weak [18]. Three different functional forms of tRNA, amino-
acyl-tRNA, peptidyl-tRNA and deacyl-tRNA, can bind si-
multaneously to the bacterial ribosome where they attach, 
primarily and respectively, to the A-, P-sites on the small 
subunit and to the E-site on the large subunit; other sites 
on the large subunit are designated T, possibly A', and P' 
[10-15,18]. During the elongation cycle tRNAs can exist in 
various physical and functional states some of which are con-
sidered separately below. 
2.1. The entry (AIT) site 
The incoming aminoacyl-tRNA, complexed with EF-
Tu.GTP in the ternary complex, binds initially at an entry 
site on the ribosome [19-21]. Experiments with ribosome-
bound ternary complexes containing non-cleavable GTP ana-
logues demonstrate that both aminoacyl-tRNA (Phe-tRNA) 
and the GTP analogue can readily exchange in this state [22]. 
The bound ternary complex protects some rRNA sites against 
chemical modification that are located exclusively on the 30S 
subunit [23]. This suggests that interactions on the large sub-
unit occur partly via interactions with ribosomal proteins [24] 
that may include interactions between EF-Tu and the 
(L12)4.L10 pentamer. This latter protein complex binds within 
a region of domain II of 23S rRNA that has been implicated 
in the ribosome-dependent GTP hydrolysis reactions [25], and 
it also constitutes the site at which bound EF-Tu has been 
mapped on the ribosome by immuno-electron microscopy 
[26]. 
In the ternary complex, the acceptor end of the aminoacyl-
tRNA lies between two structural domains of the EF-Tu 
structure, in a constrained conformation [27]. However, the 
capacity of Phe-tRNA, carrying an azido group at the 2 posi-
tion of the 3'-terminal A76 (2-azidoA76Phe-tRNA), to cross-
link within positions 1930-1980 of domain IV of 23S rRNA 
(fragment F5, Fig. 2), when bound in a ternary complex con-
taining the non-hydrolysable GTP derivative GMP-PNP [28], 
suggests that 23S rRNA can gain access to this groove. On 
GTP hydrolysis, the 3'-end of the tRNA is released and is free 
to move across the 50S subunit into the peptidyl transferase 
centre [29]. 
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2.2. Pre-peptide bond forming state(s) 
After release from the ternary complex, and prior to peptide 
bond formation, the 3'-end of the aminoacyl-tRNA enters the 
catalytic centre. This region of the ribosome corresponds to 
the A'-component of an A/A'-site that had a prominent role 
in an earlier model in providing a reciprocating binding site 
for aminoacyl- and peptidyl-tRNA. A consequence of the 
hybrid state model is that no discrete, relatively stable binding 
is required. This is a region through which the 3'-end of the 
tRNA must pass, transiently, before entering the transition 
state for peptide bond formation. At present, we have no 
estimate of how far the 3'-end of aminoacyl-tRNA moves in 
this step. 
It is now clear, for many of the early experiments, that it 
was not an A'-like site that was primarily being investigated 
but rather the P'-component of the hybrid A/P'-site (see be-
low). Included in this category are experiments in which (a) 
the P/P'-site was blocked with deacylated tRNA and an ami-
noacyl-tRNA, or derivative thereof, was cross-linked to, or 
probed on, the ribosome [30-32]; (b) a puromycin derivative 
was cross-linked to an unlocalised GUUCG (or GUCCG) 
sequence within the large subunit rRNA [33-35]; and (c) com-
petitive binding studies between antibiotics and aminoacyl-
oligonucleotides [36], since the latter, and at least some of 
the former, can bind in the P'-site [37]. 
Moreover, there is evidence that the region of the ribosome, 
through which the 3'-end of the aminoacyl-tRNA passes, is 
conformationally heterogeneous on the free ribosome [38]. 
Circumstantial evidence suggests that the acceptor substrate 
region of the tRNA interacts there [39,40] since, first, puro-
mycin can bind and react with a donor substrate [41], second, 
both the accuracy and rate of elongation are affected in a 
systematic way by mutations in the 23S rRNA [42,43] and, 
third, peptidyl transferase antibiotics can modulate the affinity 
of aminoacyl-tRNA for the ribosome, after GTP hydrolysis 
and release of EF-Tu-GDP [44,45]. However, interactions ap-
pear to have a low degree of site specificity [46] and, more-
over, mutational studies of the -CCA sequence of the acceptor 
substrate revealed a low level of base specificity, although 
changes in the 3'-terminal-CA sequence did produce some 
lowering of acceptor activities in the 'fragment' reaction [47]. 
Attempts to determine the protein environment of this ri-
bosomal region yielded fairly complex protein patterns 
[24,48]. Parallel studies have been performed to characterise 
an rRNA component of this region. They include: (i) foot-
printing of tRNA-ribosome complexes on 50S subunits [49]; 
(ii) RNA footprinting of puromycin, and other supposed A'-
site-specific drugs, on ribosomes [50-52]; (iii) site-directed mu-
tagenesis of the peptidyl transferase loop [53], and (iv) affinity 
probing experiments between the 5'-end of ribosome-bound-
tRNA and 23S rRNA [54]. None of these data are readily 
reconcilable with a discrete, relatively stable, A'-site on the 
50S subunit. 
One promising approach used to investigate this region of 
the 50S subunit was to fill the P/P'-site with AcPhe-
tRNAox_red, for which the 2'-3' bond of the 3'-terminal ribose 
is cleaved. This peptidyl-tRNA analogue lacks donor activity 
but binds with thermodynamic and kinetic parameters similar 
to those of AcPhe-tRNA [55,56]. Subsequently, Phe-tRNA is 
bound to the ribosome either within a ternary complex or 
alone. The former produces the more stable complex, as 
judged by its lower rate of exchange with unlabelled Phe-
tRNA in solution and, consistent with this, the former also 
exhibits a slower dissociation rate [22,56]. The results were 
confirmed by binding in the presence of tetracycline, which 
perturbs tRNA binding on the 30S subunit; Phe-tRNA com-
plexed via a ternary complex bound at a lower rate whereas 
free Phe-tRNA bound with a 10-fold lower apparent associa-
tion constant. These differences are consistent with the 3'-end 
of the tRNA existing in different states immediately prior to 
peptide bond formation possibly reflecting that conforma-
tional changes are induced in the aminoacyl-tRNA and/or 
the ribosome as a result of EF-Tu-dependent GTP hydrolysis 
[57]. 
2.3. Hybrid AIP' site 
The activated complex decays after peptide bond formation 
and the peptidyl-tRNA enters the relatively stable A/P'-site. 
Moreover, when peptidyl-tRNA is added to ribosomes carry-
ing deacylated-tRNA in the P/P'-site, it does not bind to an 
A/A'-site but rather enters the A/P'-site directly. The latter 
hypothesis was established using an in vitro system where 
translocation was inhibited by adding viomycin or kanamy-
cin; both AcPhe-tRNA and AcPhePhe-tRNA reacted with 
puromycin when they were bound to ribosomes carrying de-
acylated-tRNA in the P/P' site [5-7]. The result was confirmed 
by a cross-linking experiment in which (2N3A76)tRNA
phe, 
bound at either the P/P'-site or the presumed A/A'-site 
(with deacylated-tRNA in the P/P'-site), was shown to 
cross-link to the same two 23S rRNA fragments, Fl (posi-
tions 2570-2590) and F2 (positions 2500-2528) [28] (Fig. 2). 
This result is consistent with the affinity labelled A76 of the 
tRNA being located at closely similar positions within the P'-
site implying, in turn, that the affinity labelled tRNAs occupy 
the P/P' and A/P'-sites, respectively. 
2.4. The PIP' site 
The P/P' site becomes filled by peptidyl-tRNA during trans-
location, a process involving movement of the anticodon arm-
mRNA complex, relative to the 30S subunit [4-7] that is 
mediated by the [EF-G-GTP] complex that, alternatively, re-
places ternary complexes on the ribosome [27,57-59]. The site 
can be filled specifically and efficiently by tRNA in vitro and, 
according to the hybrid state model, at least one component 
of the site (P or P') is always occupied during the elongation 
cycle (Fig. 1). All three functional forms of tRNA (aminoacyl-
tRNA, peptidyl-tRNA and deacylated tRNA) have a higher 
affinity for this site (10-50-fold, depending on the magnesium 
concentration) than for the A/P'-site [55,60-65]. The relative 
binding affinities are: deacylated tRNA>Phe- tRNA>Ac-
Phe-tRNA [55,64] which also correlates with the observation 
that the 3'-pentanucleotide fragment CACCA-Phe binds at 
least as strongly as its acetylated form [37]. Importantly, the 
affinity of the 3'-end of the tRNA for this site on the free 50S 
subunit (for both Phe-tRNA and pentanucleotide fragments) 
is undetectable in aqueous solution but is enhanced by at least 
3-5 orders of magnitude in the presence of 20-50% alcohol 
[15,66]. Thus, for yeast deacylated-tRNApho, bound at the P/ 
P'-site in the presence of poly(U), the CCA-end contributes 
only about 17%o of the total standard free energy change of 
the tRNA-ribosome interaction (53.6 kJ/mol) divided as fol-
lows: A76 2.4 kJ/mol, C75 3.0 kJ/mol, C74 3.9 kJ/mol [67], 
while for the peptidyl-tRNA, this contribution is likely to be 
even less because of its lower overall affinity for the P/P'-site 
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and since the peptide moiety is unlikely to weaken the bind-
ing. 
Various lines of evidence indicate that the P'-site is com-
posed primarily of rRNA. These include the inactivation of 
peptide bond formation by RNase Ti treatment [68] and flu-
orescence quenching effects on dyes attached near the 3'-end 
of tRNAphe [69]. Furthermore, studies on donor-substrate 
specificity have revealed a minimal requirement for an N-
blocked CCA-aminoacyl fragment, although the very low ac-
tivities observed for N-blocked di- and mononucleotide sub-
strates [70,71] suggest that they carry residual structural and 
functional specificity. Interactions of the 3'-terminal CC se-
quence of the peptidyl-tRNA probably contribute to the over-
all specificity, since both cytosine residues are protected 
against chemical modification by the 50S subunit when de-
acylated-tRNAphe is bound in the putative P/P'-site (see be-
low) in the presence of poly(U) [30,72]. Moreover, the CCA 
sequence has been implicated by footprinting experiments in 
binding to two distinct sites on 23S-like rRNA: the dinucleo-
tide G-G2253, and nucleotides U2585, U2584 and U2506 clustered 
at the base of the peptidyl transferase loop [49] (Fig. 2). The 
latter results are consistent with the "zero-length" cross-links 
induced by ultraviolet radiation between P/P'-site-bound 
(2N3A76)tRNA
phe and 23S rRNA fragments Fl (positions 
2570-2590) and F2 (positions 2500-2528) [28] (Fig. 2). For 
the G-G2253 sequence, evidence for a base-pairing interaction 
forming in vitro between C74 (in the conserved sequence C74-
C-A of P'-site-bound tRNA) and G2252 was obtained [73], and 
confirmed [74], using a compensatory base change approach. 
In contrast, no evidence was found for Watson-Crick pairing 
in the lower part of the peptidyl transferase loop, using either 
rRNA mutagenesis approaches [74,75] or a similar compensa-
tory base change approach [74], although the latter data were 
compatible with a Hoogsteen pair forming between A76 of the 
tRNA and U2585 [74]. 
Interpretation of these results is complicated by the strong 
evidence for AcPhe-tRNA and deacylated tRNA binding in 
different states within the putative P/P'-site of ribosomes 
which is outlined below. 
(1) Affinity constants and other thermodynamic and kinetic 
parameters are different for ribosomal binding of AcPhe-
tRNA and deacylated tRNA, as is the Mg2+ concentration 
dependence of their binding in the absence or presence of 
mRNA [64]. For example, in the absence of poly(U), the slope 
of the dependence curve for log K& (association constant for 
tRNA binding) versus log [Mg2+] was 8 for AcPhe-tRNA and 
3 for deacylated-tRNA; while in the presence of poly(U) 
the slope was 4 for AcPhe-tRNA and 5 for deacylated-tRNA 
[64]. 
(2) Energy transfer measurements for different fluorescence 
probes attached to ribosome-bound tRNAs and fluorescein 
acceptor probes attached to proteins S21, LI or LI 1, as well 
as differences in the quantum yields of fluorescence for the 
tRNA-bound probes, all indicate that AcPhe-tRNA and de-
acylated-tRNA are located in different structural environ-
ments [76-78]. Moreover, the results were similar when de-
acylated-tRNA was bound directly to the P/P'-site or when 
it entered this site via the peptidyl transfer reaction. 
(3) AcPhe-tRNA carrying 8-N3A at position A73, which 
was bound at the P/P'-site, cross-linked primarily to 23S 
rRNA and to a lesser degree to proteins L2 and L27 on ultra-
violet irradiation, whereas deacylated-tRNA carrying an 8-
N3-adenosine at either position A73 or A76 cross-linked exclu-
sively to protein L27 [79]. 
(4) The chemical footprints produced by AcPhe-tRNA and 
deacylated-tRNA on 23S rRNA and 16S rRNA are not iden-
tical [4,49]. Thus, A2439 and A2451 were protected on 23S 
rRNA by P/P'-site-bound AcPhe-tRNA but not by deacyl-
ated-tRNA, while the reactivity of A2602 was enhanced only 
by AcPhe-tRNA binding [49]; these different reactivities may, 
or may not, be induced by the N-blocked aminoacyl-moiety. 
Similarly, for 16S RNA, deacylated-tRNA produced stronger 
protection of Gi33g and higher reactivity at A7o2 compared 
with AcPhe-tRNA [4]. 
One interpretation of these differences is that the 3'-end of 
peptidyl-tRNA binds, as the donor substrate, in the P'-site 
while the 3'-end of deacylated tRNA occupies a site inter-
mediate between the P'- and E-sites with the remainder of 
both tRNAs occupying the same, or strongly overlapping sites 
on the 30S subunit. This interpretation would also explain the 
observation that deacylated-tRNA (the product of peptidyl 
transfer) has a higher affinity than peptidyl-tRNA (the sub-
strate of peptidyl transferase) for the presumed P/P'-site, i.e. 
the former is partially displaced from this site. 
An alternative explanation is that the 3'-end of peptidyl-
tRNA moves from the P'-site after the aminoacyl-tRNA is 
released from the ternary complex (or bound non-enzymati-
cally), and immediately prior to peptidyl transfer, i.e. during 
formation of a short lived transition state for peptide bond 
formation (Fig. 3). This scenario would provide a rationale 
for the apparent inconsistency between the low contribution 
of C74 to the free energy of tRNA binding at the P/P'-site 
( < 1 kcal/mol) [67] and the three hydrogen bonds ( ~ 4-5 
kcal/mol) required for the above-mentioned putative Wat-
son-Crick base pair interaction between C74 and G2252 [73]. 
Thus, the latter interaction may constitute a short-lived inter-
action important for the formation of the transition state. 
After peptide bond formation, the activated complex would 
decay leaving the peptidyl-tRNA in the A/P'-site and deacyl-
ated tRNA in the P/E-site. 
2.5. Hybrid PIE-site 
Substantial movement of the 5'-end of the peptidyl-tRNA 
occurs, relative to the ribosome, concomitantly with peptide 
bond formation [76,78,80] that corresponds to movement of 
the newly deacylated tRNA from the P/P'- to the P/E-site. 
This movement results in the disappearance of a P/P'-site 
footprint on 23S rRNA (strong protection of G2252, G2253, 
U2506, U2584, U2585) and the appearance of an E-site footprint 
(strong protection of C2394, weak protection of G2112, and 
G2116), while the corresponding footprint on the 16S rRNA 
remains unchanged (protection of G693, A794, C7g5 and G926) 
[4]. 
2.6. The E-site 
During translocation, the deacylated tRNA enters the E-site 
[12-14,81-83], which is specific for this tRNA and is located 
primarily, or exclusively, on the large subunit [13-15,84,85]. 
Deacylated-tRNA binds at least 2000 times more strongly to 
the E-site (on either 50S subunits or 70S ribosomes) than to 
the P'-site, on the free 50S subunit, where binding is only 
detectable in water-alcohol mixtures [15]. Moreover, it resides 
there transiently before leaving the ribosome after transloca-
tion [85,86]. The following circumstantial evidence suggests 
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Fig. 1. The hybrid state model for peptide elongation is presented in a schematic form, modified from [4], where the sequential binding sites of 
tRNA during peptide bond formation are illustrated. This version of the model assumes that no major dislocation of the subunits occurs dur-
ing the elongation cycle and a discrete A/A'-binding site is omitted (see text for discussion). 
that the E-site substrate interacts with rRNA: (1) the 3'-ter-
minal adenosine is important for ribosomal binding [13,86]; 
(2) chemical probing of E-site-bound deacylated tRNA re-
vealed protection effects on the 23S rRNA (see above), and 
(3) deacylated (2N3A76)tRNA
phe bound to ribosomes pro-
grammed with poly(U) when the P/P'-site, and putative A/ 
A'-site, are occupied by two copies of AcPhe-tRNAplle, 
cross-linked specifically to fragment F3 of 23S rRNA (posi-
tions 2300-2360, Fig. 2A) [28]. Since fragment F3 falls in the 
rRNA region where the 5S rRNA-L18,L5 complex attaches 
[87], and yields a footprint [88], on the 23S rRNA, the long 
sought after function of 5S rRNA may be to mediate move-
ment of the 3'-end of tRNA. 
Surprisingly, when (2N3A76)tRNAphe was bound directly to 
either 50S subunits or 70S ribosomes, where the P/P'-site was 
occupied by deacylated-tRNALys coupled to poly(A), no 
cross-links to the 23S rRNA were detected. However, both 
complexes produced cross-links to protein L33, and it yielded 
additional cross-links between azidoadenosine, at position 37 
(substituted wyosine), and protein Sll and the 3'-end of 16S 
RNA [28,89]. These complex cross-linking patterns may re-
flect binding to different states within the E-site or to sites 
intermediate between the P/P'- and E-sites. 
3. The nascent peptide 
Fluorescence data have provided strong evidence that the 
nascent peptide moves away from the catalytic centre concom-
itantly with each round of peptide bond formation [76,78]. 
The peptide passes along a passage that constitutes either a 
tunnel through the large subunit [90-92] or a surface channel 
[93], and the nascent protein assembles on the outer surface of 
the larger subunit [94,95]. Some progress has been made in 
mapping the sequential ordering of ribosomal components 
along the peptide passage; in particular, proteins L2 and 
L16 are located near the entrance to the passage ([96] and 
references therein). Some nascent homopolypeptides do not 
enter this passage and they include polyphenylalanine that 
forms a hydrophobic aggregate in the immediate vicinity of 
the peptidyl transferase centre [97-100]. This observation 
complicates the interpretation of in vitro assays for both pep-
tide elongation and its inhibition by antibiotics. 
4. The peptidyl transferase loop and its functional sub-sites 
The peptidyl transferase centre on the large subunit [17] is 
rich in rRNA and includes the highly conserved central loop 
region in domain V of the 23S-like rRNA [101], although the 
G-G2253 region of domain V [73] and a highly conserved re-
gion of domain IV [54,102-105] also contribute to the centre. 
There are also indications that 23S rRNA contributes directly 
to the catalytic process [106] and although no catalytic groups 
have been identified, the possible involvement of a 5'-terminal 
phosphate group [107] or a pseudouridine residue (e.g. at 
positions 2554 and 2580, Fig. 4A) has been considered (re-
viewed in [108]). 
An attempt was made, recently, to define functional sub-
sites within the peptidyl transferase loop region [51,53]. Data 
from various sources was utilised including: (a) footprinting 
data obtained from chemically altered tRNAs complexed with 
ribosomes [49]; (b) location of antibiotic sites within the pep-
tidyl transferase centre [50-52], and (c) literature data on the 
modes of action of antibiotics [109-111]. The working model 
Domain IV 
peptidyl 
transferase 
loop 
Domain V 
Fig. 2. Regions of 23S rRNA implicated in the binding and/or 
movement of the 3'-end of tRNA at the peptidyl transferase centre. 
An outline of the secondary structure of domains IV and V of E. 
coli 23S rRNA are shown that generate the peptidyl transferase 
centre. RNA regions that have been implicated in the binding of 
the 3'-ends of tRNAs bound at the P'-site or E-site are indicated 
[49], as are the rRNA fragments Fl, F2, F3 and F5 that are cross-
linked to the affinity labelled (2N3A76)tRNA
phe [28] bound in differ-
ent tRNA sites (see text for details). 
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Fig. 3. Schematic representation of a model for different binding states of the 3'-end of the donor substrate within the P'-site, where a distinc-
tion is made between an initial binding state and an activated form in the transition state during peptide bond formation. In A the peptidyl-
tRNA resides in an initial binding site and is activated on release of aminoacyl-tRNA from the ternary complex whereas in B the peptidyl-
tRNA binds initially in the activated state. The A- and P-sites on the small subunit are indicated, as are the T-, P'- and E-sites on the large 
subunit (see also Fig. 1). Amino acids are represented by filled circles while the donor substrate aminoacyl residue is depicted as an open circle; 
the catalytic centre is boxed. 
is presented in Fig. 4A alongside data relating to the binding 
of antibiotics in the peptidyl transferase centre (Fig. 4B). It 
remains tentative given the high degree of structural and func-
tional cooperativity that occurs within this centre. The as-
signed sub-sites include the P'- and E-sites and the entrance 
to the peptide channel, mentioned above; others include (a) 
the assignment of A2439 close to the catalytic centre based on 
its likely protection by the aminoacyl residue of the peptidyl-
tRNA [32,49] and its reactivity being affected by many pep-
tidyl transferase antibiotics [51], and (b) a hydrophobic site 
for binding aromatic aminoacyl residues and possibly aro-
matic antibiotics (see below) centred on A-C2452 [51]. 
The peptidyl transferase centre may be physically shielded 
during peptide elongation in order to protect the ester bond, 
which links the nascent peptide to its tRNA, from hydrolysis 
by small nucleophilic molecules [9]. That such strong hydrol-
ysis can occur was demonstrated for deacylated tRNA, or a 
-CCA fragment, bound to ribosomes carrying P/P'-site-bound 
fMet-tRNA™6', under the solution conditions of the 'frag-
ment' reaction that includes 20% ethanol; fMet-ethyl ester 
was produced, presumably catalysed by the peptidyl transfer-
ase [112]. A similar reaction occurs for aminoacyl-oligonu-
cleotides bound to free ribosomes [46]. In the former study, 
both the rate and yield of the reaction was strongly reduced in 
the presence of aminoacyl-tRNA (when peptide bond forma-
tion occurs), and by peptidyl transferase inhibitors including 
amicetin, chloramphenicol and sparsomycin [112]. This sug-
gests that the aminoacyl moiety, and the antibiotics, can, di-
rectly or indirectly, protect the ester bond of the fMet-tRNA. 
These results provided the basis for a model [9] in which the 
3'-end of the aminoacyl-tRNA, and some antibiotics, bind to 
the ribosome and induce opening of the catalytic centre, and 
facilitate their own access to the catalytic centre which then 
closes, thereby effecting protection of the ester bond. A more 
static view of the observed ethanolysis is that a deacylated 
tRNA, anchored at the A(30S)-site, stabilises an ethanol 
molecule in the acceptor substrate position that can hydro-
lyse the ester bond of the peptidyl-tRNA and that can also 
be displaced by adding aminoacyl-tRNA or certain antibiot-
ics. 
5. The peptidyl-transferase antibiotics 
Peptidyl transferase antibiotics are paradoxical in that they 
show a diverse range of chemical structures, yet appear to 
influence one catalytic centre on the large subunit [109-111]. 
However, the catalytic reaction is unusual; the substrates -
the amino group of the incoming aminoacyl-tRNA and the 
carbonyl group of peptidyl-tRNA - are connected to complex 
tRNA molecules which have much stronger interactions with 
the ribosome-mRNA complex than do the substrates them-
selves at the catalytic centre [18]. Consequently, any antibiotic 
that interacts with any part of the tRNA - or interferes with 
the tRNA-ribosome interactions that are important for tRNA 
and/or ribosomal movement - can, in principle, produce dis-
tortions at the CCA-end of the acceptor or donor substrates 
and, thereby, inhibit the formation of a peptide bond. Thus, 
there could be as many different antibiotic binding sites, and 
inhibitory mechanisms, as there are different antibiotics. 
Designating the inhibitory mechanisms of peptidyl transfer-
ase antibiotics has, to a large degree, been based on their 
capacity to prevent puromycin reacting with either N-acetyl-
ated aminoacyl-tRNA or, more commonly, the truncated 3'-
terminal A^-acetylated aminoacyl-CACCA fragment. How-
ever, this reaction, in itself, is problematic, first, because it is 
multi-step, both spatially and temporally [113] and, second, 
because binding of the donor fragment requires the presence 
of about 30% ethanol [36,114] which, in turn, weakens pur-
omycin binding [115]. 
Another approach has been to study competitive binding 
between drugs and aminoacyl-CACCA fragments for a puta-
tive A'-site. For example, it was shown that many peptidyl 
transferase antibiotics inhibited binding of CACCA-Phe to 
ribosomes and they were designated A'-site inhibitors [113]. 
However, the pentanucleotide (and trinucleotide) fragments, 
carrying amino acids, can bind with an affinity similar to their 
Af-acetylated derivatives to the P'-site [37] and, moreover, two 
copies of CACCA(3'NH)Phe were shown to bind coopera-
tively to the ribosome [116]. The latter observations invalidate 
earlier interpretations of the competition binding experiments 
between drugs and aminoacyl-CACCA fragments. A further 
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complication, especially for the early experiments, is that sub-
stantial amounts of peptidyl- tRNA remained bound to ribo-
somes despite multiple high salt washes [46,117], This can 
often be seen for antibiotic inhibition studies where sparso-
mycin was tested since it only binds to a ribosome when 
peptidyl- tRNA is bound [118], Moreover, in many experi-
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Fig. 6. A: Structure of sparsomycin; B: a model for how the modified uracil of sparsomycin may generate a base triple, together with the pu-
tative A76-U2585 Hoogsteen pairing between peptidyl-tRNA and 23S-like rRNA [74], which could explain the drug-induced stabilization of the 
P'-site substrate within the peptidyl transferase centre. 
merits, attempts were made to remove residual peptidyl-tRNA 
by incubating ribosomes with puromycin (e.g. [46]), however, 
this treatment may leave deacylated tRNA bound in the P/E-
site and, possibly, peptidyl-puromycin chains trapped in the 
peptide passage. Therefore, few of these experiments are ame-
nable to straightforward reinterpretation in terms of the hy-
brid state model. 
Nevertheless, there are strong indications that peptidyl 
transferase antibiotics can be classified into a few major struc-
tural and functional categories. Two of the best characterised 
groups include (a) those drugs that are to some degree co-
structural with the 3'-end of aminoacyl-tRNA and prevent it 
forming a peptide bond and (b) those that perturb the move-
ment and/or positioning of the nascent peptide (see Table 1). 
In general, antibiotics can be assigned to one of these two 
groups on the basis of their capacity to bind to polysomes 
because, according to the hybrid state model, polysome-
bound tRNAs occupy either the hybrid A/P'- and P/E-sites 
or the P/P'-site i.e. the P'-sites and some of the E-sites on the 
large subunits will be filled. Therefore, drugs that affect the 
region through which the acceptor substrate passes, prior to 
peptide bond formation, should bind while those that act 
primarily in the peptide binding region, or at the P'-site 
(and possibly the E-site), should neither bind to polysomes 
Table 1 
Examples of different antibiotics that perturb and/or inhibit the 
movement of the 3'-end of tRNA through the peptidyl transferase 
centre 
Acceptor substrate 
Anisomycin 
Chloramphenicol 
Puromycin 
Cvtosine derivatives 
Amicetin 
Blasticidin S 
Gougerotin 
-* 
Lincosamides 
Lincomycin 
Celesticetin — 
P -site 
Sparsomycin 
Streptooramin A 
Virginiamycin M1 
Griseoviridin 
Peptide 
Macrolides 
Erythromycin 
Carbomycin 
Tylosin 
Streptogramin B 
The likely sites of perturbation, acceptor substrate, P'-site or nas-
cent peptide are indicated in italics. 
nor compete with puromycin. Examples of these two groups 
of drugs are given in Table 1. 
5.1. Antibiotics primarily affecting peptide bond formation 
Many drugs, including puromycin, are to some degree co-
structural with the 3'-end of aminoacyl-tRNA (Fig. 5) and 
have been considered to bind to the ribosome in competition 
with aminoacyl-tRNA analogues and some, but not all, bind 
competitively with one another [46,119]. They include aniso-
mycin, chloramphenicol and the modified cytosine drugs 
althiomycin, amicetin, blasticidin S and gougerotin (Fig. 5), 
and they have generally been considered to block, directly or 
indirectly, the binding of the 3'-end of aminoacyl-tRNA to an 
A'-site [109-111,120-125]. More recently, in the context of the 
hybrid state model, it has been considered that they might act 
primarily by blocking movement of the 3'-end of the amino-
acyl-tRNA immediately after release from the ternary com-
plex [9,126]. This hypothesis is consistent with the observation 
that these drugs bind to, and inactivate, isolated polysomes 
where residual peptidyl-tRNAs are bound in the A/P'- or P/ 
P'-sites with deacylated-tRNAs in the P/E-site or dissociated 
from the E-site, respectively [127]. 
5.7.7. Chloramphenicol. Chloramphenicol is generally rep-
resented as a competitor, and structural analogue, of puromy-
cin (Fig. 5) and is assumed to interfere with the 3'-end of the 
acceptor substrate [41]. Various binding studies reinforce this 
view although the partial competition, often observed, leaves 
some doubt as to whether this is an exclusive inhibitory site 
for the drug [36]. It was demonstrated earlier that chloram-
phenicol has two binding sites on 50S subunits, a stronger one 
(7Cd = 2 x l 0 -
6 M) and a weaker one (7d = 2 x l 0 - 4 M) [36]. 
Although only the stronger bound drug molecule inhibits the 
fragment reaction between CACCA-Leu-Ac and puromycin 
[41]; this does not exclude the possibility that chlorampheni-
col can inhibit by binding at another site which overlaps with 
that of erythromycin. In favour of this view is (a) the obser-
vation that a G2057A mutation in the peptidyl transferase 
loop confers resistance against both chloramphenicol and ery-
thromycin (but not other macrolides) [128], (b) the finding 
that erythromycin competes with chloramphenicol for binding 
to 70S ribosomes but cannot displace chloramphenicol from 
polysomes (to which only chloramphenicol binds) [127], (c) 
like erythromycin, chloramphenicol destabilises peptidyl-
tRNA binding, enhancing the release of Ac(Phe)2-tRNA 
and Lys2-tRNA from the ribosome [129-131]. 
A possible explanation for these effects, given the lack of 
direct evidence for two different binding sites, is that chlor-
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amphenicol can remain bound on the ribosome to alternative, 
and mutually exclusive, conformers within the peptidyl trans-
ferase loop region [66] and this could also explain: (a) why 
single-site mutations of at least 10 different nucleotides in the 
peptidyl transferase loop region can confer chloramphenicol 
resistance [101] and (b) why chloramphenicol produces partial 
protection of at least five nucleotides within this region 
against chemical modification (Fig. 4B) at positions that 
show minimal overlap with those produced by puromycin 
[52]. 
5.1.2. Sparsomycin. Sparsomycin is a highly potent, broad 
spectrum, antibiotic that strongly inhibits the 'fragment' assay 
for peptide bond formation [132]. It binds to the ribosome 
only when the P/P'-site is occupied by an N-blocked substrate, 
i.e. it does not inhibit formation of the first peptide bond on 
the eukaryotic ribosome [118]. It stabilises, and enhances, the 
binding of the TV-blocked donor substrate in the P'-site [133 
135] and destabilises, in some unknown way, binding of the 
ternary complex [113,136]. Binding studies with various spar-
somycin derivatives revealed two important groups, at either 
end of a fairly rigid molecule (Fig. 6A), that interact with the 
ribosome-tRNA complex [137,138]; an S-CH3 group and a 
methylated uracil residue that carries a pseudouridine-like 
linkage to a peptide-like grouping [139]. Although the modi-
fied uracil can potentially base pair with rRNA, in contrast to 
the results obtained for many other peptidyl transferase drugs, 
footprinting studies failed to reveal evidence of an rRNA 
binding site for the drug [51,135]. Evidence for an rRNA 
interaction is less direct and rests mainly on the observation 
that single-site mutations within the peptidyl transferase loop 
of archaeal 23S-like rRNAs can confer sparsomycin resistance 
[140,141]. These mutated sites correspond to lack of a methyl 
group on U2584 and a C2499U mutation, in haloarchaeal 23S 
rRNA, and they are located within, or near, the P'-substrate 
site (Fig. 4A) consistent with sparsomycin affecting primarily 
this site. 
The turnover of aminoacyl-tRNA is increased in the pres-
ence of sparsomycin [136] and this may reflect hindrance, 
direct or indirect, of the binding of the ternary complex 
and/or access of the 3'-end of the aminoacyl-tRNA to the 
catalytic centre. The most likely interpretation of this is that 
it overlaps into the acceptor substrate domain of the peptidyl 
transferase centre, mimicking to some extent, the structure of 
the terminal adenosine and amino acyl residue (see sparso-
phenicol structure in Fig. 5). This is consistent with it binding 
to polysomes [66] and explains its competing surprisingly 
strongly with puromycin, as well as with chloramphenicol, 
lincomycin and the larger (16 carbon ring) macrolides such 
as tylosin [118] that appear to extend into the catalytic centre 
(see below). 
The experimental evidence suggests that the drug has a 
fairly intimate interaction with the 3'-end of peptidyl-tRNA 
on the ribosome and the universality of the drug action points 
to highly conserved interactions. Both U2585 and some neigh-
bouring nucleotides, as well as in the 3'-end of tRNA are 
universally conserved [74]. Whether the blocked amino group 
of the first amino acid is important for the drug interaction or 
for fixing the first aminoacyl residue in the catalytic centre is 
unclear. There is some evidence in support of the latter [141] 
that does not necessarily exclude the former. Moreover, the 
observation that an amicetin-resistant mutant, carrying the 
change C2438U, is also sparsomycin-resistant [9] may support 
this. A possible interaction between the methylated uracil res-
idue, A76 of the peptidyl tRNA and U2585 of the 23S-like 
rRNA is presented (Fig. 6). 
5.1.3. Other peptide bond inhibitors. There are many other 
antibiotics that affect peptide bond formation, directly or in-
directly, some of which are indicated in Fig. 4B, for which 
relatively little is known about their mechanism of inhibition. 
These include the alkaloid drugs bruceantin and narciclasine, 
as well as toxin T2. The streptogramin A drugs, however, 
constitute an important group. They inhibit elongation coop-
eratively with streptogramin B drugs which are related, in 
their mode of action, to the macrolides and lincosamides 
[142]. Paradoxically, prebound streptogramin B prevents bind-
ing of streptogramin A [110,111,142] which led to the sugges-
tion that the latter may enter the catalytic cavity via the pep-
tide passage [9]. Moreover, fluorescence measurements 
suggested that it acts primarily within the P'-site [143]. The 
RNA footprint produced by streptogramin A (virginiamycin 
Mi) and the related griseoviridin (Fig. 4B) are very complex 
suggesting that they produce substantial changes in the pep-
tidyl transferase loop region. One of the sites affected by 
streptogramin A is exceptional in that it occurs at C2394 that 
has been implicated in the E-site (Fig. 4A). Thus, streptogra-
min A may act by preventing movement of peptidyl-tRNA 
from the P/P'-site to the P/E-site. Clearly, further experimen-
tal work is necessary on the mechanism of action of these 
drugs now that we have an improved model for peptide elon-
gation. 
5.2. Antibiotics primarily affecting the nascent peptide 
Another large group of antibiotics, again with diverse struc-
tures, consists of the macrolides, lincosamides and streptogra-
min B (MLS) drugs. The macrolide and streptogramin B 
drugs, at least, appear to share overlapping binding sites 
near the entrance to the peptide passage (Fig. 4A), where 
they probably hinder movement, and/or perturb binding, of 
the peptide moiety of the peptidyl-tRNA, a process which 
may also lead to destabilisation of the peptidyl-tRNA bound 
in the P/P'-site. The primary evidence for their sharing com-
mon binding sites around nucleotides 2057-2062 and 2609-
2611 at the start of the peptide passage is as follows. (1) 
Organisms producing macrolides and lincosamides protect 
their own ribosomes by N6-mono- or di-methylated A2058 
[25,144]. (2) Several single-site mutations in this region confer 
macrolide resistance (reviewed in [145]). (3) RNA modifica-
tion studies yield altered reactivities in the presence of macro-
lides, especially in the region A2os8 to A2o62 [101,146-148] 
(Fig. 4B). (4) Finally, peptidyl-tRNAs carrying affinity-la-
belled peptides of length 1^1 amino acids cross-link to posi-
tions A2609 and A2062 [96]. These results are reinforced by 
footprinting of naturally occurring peptides that attenuate 
translation and bind competitively with erythromycin; protec-
tion was seen at positions 2058, 2059 and 2060 [149]. It is 
likely that A2058 occupies a key position in this site and since 
its reactivity is affected by both MLS antibiotics and by others 
(anisomycin, chloramphenicol) that probably do not act di-
rectly in the peptide channel, it is likely to be pivotal in de-
termining the local conformation. It is also universally con-
served amongst bacteria and only organisms from this domain 
of life are strongly susceptible to this group of drugs. 
In general, the MLS drugs appear to inhibit movement of 
the nascent peptide after a few rounds of peptide bond for-
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mation [150] but cannot inhibit when the peptide has reached 
a certain length in vivo [151]. Consistent with these observa-
tions, the drugs do not inhibit elongation on isolated poly-
somes where the A/P'- or P/P'-sites are filled, and where the 
start of the peptide passage is occupied by the nascent peptide 
[66,127,152]. However, the individual inhibitory mechanisms 
may be more complex and dependent, to some extent, on the 
size of the drug. The larger macrolides (e.g. carbomycin) are 
more effective inhibitors of the peptide-puromycin reaction 
than the smaller ones (e.g. erythromycin) [153], which may 
reflect the fact that they can extend into, and perturb, the 
catalytic centre. There are also strong indications that the 
lincosamides may behave similarly [142]. The primary inhib-
itory mechanisms of blocking movement of the peptide into 
the peptide passage would also provide an explanation for 
other inhibitory functions attributed to the drugs earlier in-
cluding both destabilisation of P/P'-site bound peptidyl-
tRNAs that have been observed both in vitro and in vivo 
[154,155] and the inhibition of the translocation reaction 
from A/P'- to P/P'-site. This inhibitory mechanism is consist-
ent with the observation that only a small fraction of the total 
free energy of tRNA-ribosome interactions derives from bind-
ing of the 3'-end of the tRNA [67,156-158]. 
5.3. Insight gained from kinetic studies of antibiotic-ribosome 
binding 
Comprehensive kinetic studies have been performed on the 
inhibitory mechanisms of many peptidyl transferase drugs. 
For example, the modified nucleoside antibiotics amicetin, 
blasticidin S and gougerotin, as well as chloramphenicol, pro-
duce biphasic curves for inhibition of peptide-bond formation 
when puromycin is used as an acceptor substrate in the pres-
ence of the donor substrate A^-acetylated Phe-tRNA. An ini-
tial competitive step (high K\) is followed by a mixed non-
competitive step (low K\) [66,159-162]. For chloramphenicol, 
the shape of the inhibition curve is sensitive to ionic strength 
and incubation temperature [163], which implies that compet-
itive and non-competitive inhibition arise from conformation-
al heterogeneity near the catalytic centre; this, in turn, could 
reflect the stabilising of different ribosomal conformers that 
form during the elongation cycle. 
In general, these effects have been attributed to a two-step 
reaction between the drug and ribosome. This involves (i) 
initial, rapid binding of the drug, near the catalytic centre, 
producing a complex where the drug displays competitive in-
hibition kinetics of peptide bond formation, followed by (ii) a 
slow conformational change of the drug-ribosome complex, 
yielding an inactive ribosomal complex. In the latter step, the 
drug is considered to stabilise a ribosomal conformer that is 
non-functional because it is reached so slowly (i.e. with a half-
time of several minutes). 
This interpretation is consistent with the drugs binding ini-
tially at a site through which the acceptor end of the amino-
acyl-tRNA passes on release from the ternary complex and 
prior to peptide-bond formation (Section 2.2). In this state, 
each drug can bind competitively with the acceptor substrate 
and with other drugs. The subsequent slow change that occurs 
may correspond to a drug-induced change in the conforma-
tion of the 23S rRNA, possibly involving an increased open-
ing or accessibility of the catalytic centre. During this change 
the drug could move closer to, or enter, the catalytic centre, 
thereby producing an inactive ribosome and non-competitive 
kinetics of drug binding. The model [9] is consistent with the 
kinetic data, in that it is quite reasonable that the latter 
should be a slower process for a drug (a partial analogue) 
than for the aminoacyl-tRNA, and equally reasonable that 
many drugs of diverse structure could act in this way. 
6. Conclusion 
A model of elongation is emerging in which the ribosome 
sequentially assumes the correct topography for binding the 
different tRNA substrates. This process places fairly narrow 
limits upon the energy of binding at each site, and upon the 
freedom of movement of the bound substrate. Above, we have 
tried to summarise some of the interactions, movements and 
possible conformational changes that precede and proceed 
peptide bond formation and attempt to explain how some 
of them may be inhibited by drug action. A major unanswered 
question concerning the antibiotics is how many independent 
sites of action they have. We consider here two major regions 
of the peptidyl transferase centre where overlapping drug 
sites, and inhibition, putatively occur, (a) A site through 
which the 3'-end of aminoacyl-tRNA moves after release 
from the ternary complex and (b) the entrance to the peptide 
passage. Other sites remain to be designated more precisely 
including where the streptogramin A-type drugs bind. Never-
theless, for most peptidyl transferase drugs, whatever the de-
tailed mechanism of inhibition, their primary mode of action 
is probably to prevent either movement of the 3'-ends of the 
tRNAs through the peptidyl transferase centre, at least partly 
by trapping a certain RNA conformer, or the movement of 
the nascent peptide away from the peptidyl transferase centre. 
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